新型抗菌药物治疗淋病奈瑟球菌感染的研究进展  

Research progress on new antibiotics in the treatment of Neisseria gonorrhoeae infection

作　　者：钟娇娇 苏晓红[1] Zhong Jiaojiao;Su Xiaohong(Institute of Dermatology,Peking Union Medical College,Chinese Academy of Medical Sciences,Nanjing 210042,China)

机构地区：[1]中国医学科学院北京协和医学院皮肤病研究所性病科,南京210042

出　　处：《新医学》2022年第11期797-801,共5页Journal of New Medicine

基　　金：中国医学科学院医学与健康科技创新工程(2016I2M-3021);美国国立卫生研究院(NIH)资助项目(AI084048,AI116969)。

摘　　要：淋病奈瑟球菌(淋球菌)是引起淋病的病原菌。随着抗菌药物的广泛使用,淋球菌的耐药性问题日益严重,近年来国内外出现对一线治疗药物(如头孢曲松钠)耐药的菌株。WHO已将淋球菌列入急需新型抗菌药物的重点病原体清单。近年来,已有多项研究探讨新型抗菌药物治疗淋球菌的疗效,包括拓扑异构酶抑制剂、新型大环内酯类、胸膜多肽类、小分子抗菌药物等。该文主要介绍上述药物的结构、体外药敏试验、耐药突变、临床试验和不良反应等研究进展,为淋球菌治疗药物的进一步研究以及临床应用提供参考。Neisseria gonorrhoeae is the pathogen of gonorrhea.With the widespread use of antibiotics,drug resistance of Neisseria gonorrhoeae is a growing problem.In recent years,drug-resistant strains to the first-line treatment drugs(such as ceftriaxone sodium)have emerged at home and abroad.The WHO has included Neisseria gonorrhoeae as one of the priority pathogens in urgent need of new antibiotics.In recent years,a number of studies have been conducted to evaluate the efficacy of novel antibiotics in the treatment of Neisseria gonorrhoeae,including topoisomerase inhibitors,novel macrolides,pleural polypeptides and small molecule antibacterial drugs,etc.In this article,research progress on the structure,in vitro drug sensitivity,drug resistance mutation,clinical trials and adverse reactions of these drugs was reviewed,aiming to provide references for further research on Neisseria gonorrhoeae and their clinical application.

关 键 词：新型抗菌药物 淋病奈瑟球菌 淋病 细菌耐药 

分 类 号：R759.2[医药卫生—皮肤病学与性病学]